anthrax vaccine adsorbed (AVA)
GPTKB entity
Statements (50)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:vaccine
|
| gptkbp:appointed_by |
injection
|
| gptkbp:approves |
gptkb:1970
gptkb:U._S._Food_and_Drug_Administration |
| gptkbp:associated_with |
gptkb:Bacillus_anthracis
|
| gptkbp:clinical_trial |
conducted for safety and efficacy
high-risk occupations |
| gptkbp:complement |
protective antigen
|
| gptkbp:contraindication |
severe allergic reactions
|
| gptkbp:developed_by |
gptkb:U._S._Army_Medical_Research_Institute_of_Infectious_Diseases
|
| gptkbp:dosage_form |
3 doses
|
| gptkbp:duration |
approximately 2 years
|
| https://www.w3.org/2000/01/rdf-schema#label |
anthrax vaccine adsorbed (AVA)
|
| gptkbp:is_used_for |
prevention of anthrax
|
| gptkbp:is_vulnerable_to |
varies by provider
intramuscular subunit vaccine supported by government and private sectors high in healthy adults based on clinical trials available through select healthcare providers based on research from the 1950s continues for improved formulations developed in response to anthrax outbreaks limited to specific populations lower in immunocompromised individuals significant in preventing anthrax outbreaks |
| gptkbp:label |
includes contraindications and warnings
|
| gptkbp:manufacturer |
gptkb:Emergent_Bio_Solutions
|
| gptkbp:notable_for |
bioterrorism preparedness
|
| gptkbp:operating_hours |
0, 7, and 21 or 28 days
|
| gptkbp:regulates |
regulated by the FDA
|
| gptkbp:requires |
every 1 to 3 years
|
| gptkbp:responds_to |
measured by antibody levels
|
| gptkbp:safety_features |
ongoing post-marketing surveillance
|
| gptkbp:side_effect |
fatigue
headache muscle pain nausea fever local reactions systemic reactions |
| gptkbp:storage |
refrigerated
|
| gptkbp:suitable_for |
gptkb:military_officer
laboratory workers |
| gptkbp:targets |
gptkb:mythological_figure
|
| gptkbp:treatment |
not recommended
|
| gptkbp:type |
inactivated vaccine
|
| gptkbp:bfsParent |
gptkb:inhalation_anthrax
|
| gptkbp:bfsLayer |
4
|